Cargando…
Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery
Since there were a few articles to report the treatment of severe pulmonary vasoconstriction induced by protamine in cardiac surgery, we described the use of epoprostenol to reverse this condition. A total of 5 cases of severe pulmonary vasoconstriction induced by protamine in cardiac surgery were r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076185/ https://www.ncbi.nlm.nih.gov/pubmed/29995750 http://dx.doi.org/10.1097/MD.0000000000010908 |
_version_ | 1783344662374776832 |
---|---|
author | Guan, Zheng Shen, Xin Zhang, Yong-Jian Li, Xiao-Gang Gao, Yan-Feng Tan, Jing Yuan, Hui Liu, Jing-Jie |
author_facet | Guan, Zheng Shen, Xin Zhang, Yong-Jian Li, Xiao-Gang Gao, Yan-Feng Tan, Jing Yuan, Hui Liu, Jing-Jie |
author_sort | Guan, Zheng |
collection | PubMed |
description | Since there were a few articles to report the treatment of severe pulmonary vasoconstriction induced by protamine in cardiac surgery, we described the use of epoprostenol to reverse this condition. A total of 5 cases of severe pulmonary vasoconstriction induced by protamine in cardiac surgery were reviewed. The demographic, clinical data and treatment process were obtained. All the patients were followed up. Severe pulmonary vasoconstriction was occurred 4 to 10 minutes after protamine infusion. The primary sign was sudden hypotension, the pulmonary artery pressure was increased gradually, the arterial oxygen partial pressure was decreased in all the patients. Epoprostenol was infused via pulmonary artery catheter at dosage of 20 to 40 ng/kg·min in all the patients, 2 patients were underwent re-cardiac pulmonary bypass assistance. The hemodynamic instability status lasted 40 to 65 minutes respectively. All the patients were recovered uneventfully. All physicians should alert to the incidence of severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Use epoprostenol through pulmonary artery catheter could treat pulmonary artery vasoconstriction effectively and safely. |
format | Online Article Text |
id | pubmed-6076185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-60761852018-08-17 Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery Guan, Zheng Shen, Xin Zhang, Yong-Jian Li, Xiao-Gang Gao, Yan-Feng Tan, Jing Yuan, Hui Liu, Jing-Jie Medicine (Baltimore) Research Article Since there were a few articles to report the treatment of severe pulmonary vasoconstriction induced by protamine in cardiac surgery, we described the use of epoprostenol to reverse this condition. A total of 5 cases of severe pulmonary vasoconstriction induced by protamine in cardiac surgery were reviewed. The demographic, clinical data and treatment process were obtained. All the patients were followed up. Severe pulmonary vasoconstriction was occurred 4 to 10 minutes after protamine infusion. The primary sign was sudden hypotension, the pulmonary artery pressure was increased gradually, the arterial oxygen partial pressure was decreased in all the patients. Epoprostenol was infused via pulmonary artery catheter at dosage of 20 to 40 ng/kg·min in all the patients, 2 patients were underwent re-cardiac pulmonary bypass assistance. The hemodynamic instability status lasted 40 to 65 minutes respectively. All the patients were recovered uneventfully. All physicians should alert to the incidence of severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Use epoprostenol through pulmonary artery catheter could treat pulmonary artery vasoconstriction effectively and safely. Wolters Kluwer Health 2018-07-13 /pmc/articles/PMC6076185/ /pubmed/29995750 http://dx.doi.org/10.1097/MD.0000000000010908 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Guan, Zheng Shen, Xin Zhang, Yong-Jian Li, Xiao-Gang Gao, Yan-Feng Tan, Jing Yuan, Hui Liu, Jing-Jie Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery |
title | Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery |
title_full | Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery |
title_fullStr | Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery |
title_full_unstemmed | Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery |
title_short | Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery |
title_sort | use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076185/ https://www.ncbi.nlm.nih.gov/pubmed/29995750 http://dx.doi.org/10.1097/MD.0000000000010908 |
work_keys_str_mv | AT guanzheng useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery AT shenxin useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery AT zhangyongjian useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery AT lixiaogang useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery AT gaoyanfeng useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery AT tanjing useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery AT yuanhui useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery AT liujingjie useofepoprostenoltotreatseverepulmonaryvasoconstrictioninducedbyprotamineincardiacsurgery |